AutoGenomics IPO Will Support Trial Of HPV Test On Infiniti Analyzer
This article was originally published in The Gray Sheet
AutoGenomics is seeking to fund a clinical study of its HPV-QUAD human papillomavirus screening test through an initial public stock offering worth up to $86.3 million (see chart: "1AutoGenomics IPO")
You may also be interested in...
Molecular diagnostics firm AutoGenomics seeks to raise up to $65 million in an initial public offering. IlluminOss raises $28 mil. for fracture repair device. LoneStar Heart gets $20 million for heart failure implant. More financings.
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.